Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02842203 · ClinicalTrials.gov registry record
Use of ctDNA for Monitoring of Stage III Colorectal Cancer
A clinical trial of Stage III Colorectal Cancer, sponsored by University of Pittsburgh.
- Active
- Registry status
- 137
- Enrollment target
- 1
- Study location
NCT02842203: Active study of Stage III Colorectal Cancer, sponsored by University of Pittsburgh.
NCT02842203 is a study of Stage III Colorectal Cancer that is active but no longer recruiting, run by University of Pittsburgh. The registered enrollment target is 137 participants, above the 61-participant average among 4 other Stage III Colorectal Cancer trials with a reported enrollment target (125% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02842203, a study of Stage III Colorectal Cancer, is active but no longer recruiting, sponsored by University of Pittsburgh.
- ACTIVE NOT RECRUITING
- Registry status
- 137 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).
Primary Outcome
The relationship between ctDNA and survival (both progression-free and overall) will be evaluated. Both the total load of ctDNA and the specific mutation(s) identified will be evaluated.
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2016-09 |
| Est. Completion | 2026-09 |
What the registry record for NCT02842203 still lists
NCT02842203 is an observational study that tracks outcomes without assigning an intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, above the 61-participant average among 4 other Stage III Colorectal Cancer trials with a reported enrollment target (125% higher).
The record links to 1 condition, with Stage III Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02842203 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02842203 about?
NCT02842203 is a clinical study titled "Use of ctDNA for Monitoring of Stage III Colorectal Cancer". This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).
What is the current status of trial NCT02842203?
This trial is currently active not recruiting. The enrollment target is 137 participants. The study started on 2016-09. Estimated completion is 2026-09.
What conditions does trial NCT02842203 study?
This clinical trial studies the following conditions: Stage III Colorectal Cancer.
Who is sponsoring clinical trial NCT02842203?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02842203 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
RECRUITING
-
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Acupuncture Pilot Study for Cancer-related Cognitive Function
ACTIVE NOT RECRUITING · Phase 2
-
Ask Questions (ASQ):Implementation of a Communication Intervention
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia